Visit us at AAOFor the first time - meet us: Booth 4656 - More
Visit us at ESCRS 2017Hall B - Booth 203 - More
Save the date June 2017Liverpool- 9./ 11. June 17 BCLA - Stand 7 & 8. More
Save the date March 2017Singapore - 2./ 5. March 17 APAO - Stand H01. More
E-Swin Vision becomes ESW Vision
To enhance the ophthalmology department created around the flagship product: E-Eye, a spin-off from E-Swin is born: ESW Vision.
Save the date Dec. 16
Iran - From 12th to 15th December 201626th Annual Congress of the Iranian Society of Ophthalmology (IrSO) at Razi Convention Centre, Tehran.
E-Eye in the world
Denmark, November 2016E-Eye goes to Denmark... now available at Eye-Clinic Bornholm (Jakob Friis).
Save the Date Nov. 2016
Italy - From 123th to 26th November 201696th SOI National Congress in Rome.
Austria, From 11th to 12th November 2016VKAA-Herbsttagung 2016 in Salzburg. 21. conference of contact-lense ophthalmologists.
Italy, 28th October 2016VIDEO CATARATTA REFRATTIVA. Successful E-Eye presentation at Dott. Buratto Congress in Milan - by NewTechSpa, with dott. Eduardo Ligabue, Luca Vigo and Luigi Marino.
E-Eye in the World
Slovenia, October 2016E-Eye treatment is available in Dr. Pfeifer 's Clinic. Dr. Pfeifer is the first Cataract Surgery Specialist in the World.
Save the date Nov. 16
Germany - 5th November 20162nd Dry Eye Workshop 2016, Munich. More
Switzerland - From 28./29. October 2016Prolens seminar on dry eye, Zürich. More
Austria - From 11th to 12th Nov. 1621. VKAA-Herbsttagung 2016, Salzburg.
China, 14th October 20162016 Ophtalmic New Technology Symposium - Sichuan Medical Association.
E-Eye in the World
South Africa, October 20161st E-Eye entered South-Africa ... WELCOME innovative E-Eye specialist Dr. Johan KRUGER with his Tygervalley Eye & Laser Clinic to E-Eye worldwide network.
E-Eye in the World
Hungary, September 2016E-Eye treatment is available in Hungary with our new partner Premed Pharma.
France, 7-10 September 2016International Conference on the Tear Film & Ocular Surfaces in MontpellierThe main French KOL - Fondation A de Rothschild and Hopital Bichat, Paris - have presented results of their study during the 8th TFOS International Conference.
Denmark, from 8 to 13 September 2016ESCRS,CopenhagenEye was a resounding success in Copenhagen.Thank you for being so many to visit us!
E-Eye in the World
Colombia, August 2016E-Eye treatment is now available in Colombia. Gustavo Neumann conducted a launching and training activities in two major accounts, FOS, Dr Virgilio Galvis and Dr G. Jaramillo.
China – May 2016Journal of OphthalmologyAn official publication of the clinical study conducted in China by Dr. Li was issued in the scientific magazine "Journal of Ophthalmology". It focuses on the evaluation of the Safety and Effectiveness of Intense Pulsed Light in the Treatment of Meibomian Gland Dysfunction with E-Eye device.
Press release of August
> Presentation by Dr. Vigo (Centro Oftalmo-Chirurgoco Carones - Milan).
Read the presentation
> Information Statement by Newtech.
Read the document
> In Starbene magazine, information for patients.
Read the article
> Publication of E-Eye advertising in "AO".
See the ad
Australia, 20-23 July 2016AUSCRS in Port Douglas. Conference of the Australian Society of Cataract and Refractive Surgeons, dedicated to ophthalmologists.
Italia, 9-11 June 2016AECOS CongresThe 6th American-European Congress of Ophthalmic Surgery was held this year at the Villa Miani in Rome.Access the presentation given in Rome by Dr Luigi Marino, in collaboration with Dr, at the conference.
Germany, 9-11 June 2016E-Swin GmbH presented the E-Eye at the 29th international congress of ophthalmological surgery in Nuremberg.
China, 28-29 May 2016The company MDC, which sponsors ophthalmology forums in the province of Hebei (in northern China), presented the E-Eye to all the ophthalmology services of the province’s hospitals, in the presence of over 300 senior consultants.
China 25 May 2016An official sales presentation of the E-Eye, organized by the company MDC, took place in the Beijing radio communication building. Dr Li Xue Min, a specialist in dry eye syndrome at Beijing’s third largest hospital, presented the device at a lecture attended by 43 distribution companies.
Taiwan – 24-27 March 2016
Darma Ltd, the subsidiary of E-Swin responsible for the Asia-Pacific region, attended the APAO Congress (Asia Pacific Academy of Ophthalmology) held in Taipei, in conjunction with the 57th annual meeting of the Taipei Ophthalmological Society.
Italia – March 2016Centre Italiano Occhio Secco This manual of 56 pages dedicated to dry eye syndrome and its treatments was written by Lucio Buratto and Luigi Marino for a prevention campaign. Discover the interpretation of these specialists on the new potential treatment provided by E-Eye (page 52).
Dubai - 14-16 April 2016
The team also introduced the E-Eye in the UAE by attending the MENA Ophthalmology Congress.
France – April 2016Réalités OphtalmologiqueIn this magazine dedicated to ophthalmic professionals, Dr. Matthew-Muselier and Dr. Creuzot-Garchera ask the question: What’s new in ocular surface? Therapeutically, E-Eye is presented as the latest technological breakthrough.
Australia - 2-3 April 2016
Our team of local experts was pleased to attend the AVC Gold Coast (Australian Vision Convention) to demonstrate the efficiency of the E-Eye.
Austria – 5-7 May 2016
E-Swin GmbH was present at the 57th annual congress of the ÖOG (Austrian Ophthalmological Society) and the 50th colloquium of the CSA in Schladming.
Australia – May 2016Equipment - Optometry Australia The Optometry Australia association presents the results obtained with E-Eye in its magazine focusing on equipment. It relies on Pr Jennifer Craig’s clinical studies and shows promising results of this new therapy, through indirect improvements in Meibomian gland function. Read more
France – 7-10 May 2016
As in the previous year, the E-Eye excited keen interest among visitors to the SFO trade fair: the 122nd congress of the French Society of Ophthalmology (SFO) at the Palais des Congrès in Paris.
About the dry eye syndrome due to Meibomian Gland Dysfunction (MGD)"The Meibomian gland dysfunction has been identified as the principal cause of dry eye syndrome throughout the world". These are the results of the first report about Meibomian Gland Dysfonction (MGD) from the ARVO (the Association for Research in Vision and Ophthalmology) conference organized in 2010. More than 50 members and some of the biggest experts in research and Ophthalmology from around the world gathered for this event. Dry eye syndrome is generally due to a Meibomian gland dysfunction, also called Blepharitis. This results in the important oil layer of our tears being unstable and thinner than it should normally be, causing an insufficient production of tears, or excessive evaporation. It is now acknowledged that the majority of evaporative cases are primarily due to the lack or insufficiency of the external lipid layer of the lacrimal film, produced by the Meibomian glands. There are approximately 80 Meibomian glands located in the upper and lower eyelids of each eye. These glands produce an oil called the lipid layer, avoiding tear evaporation and adapting tears to the irregularities of the eye surface. Lipids are made of polarized fatty acids. Their fluidity is ensured by the body temperature. They are non-polarised on the surface, giving stability to the lacrymal fluid and allowing the lubrication of the palpebral conjunctival plan. The contraction of the Riolan muscle allows the lacrymal film to spread out.
Target, symptoms & causes
PopulationDry eye Syndrome (DES) (Dry Eye Disease, DED) is a common pathology affecting up to 30% of certain adult population groups depending on the region and 40% of people wearing contact lenses or glasses. It is recognised that a large majority of dry eye cases is caused by Meibomian Glands Dysfunction (MGD).
RiskAffecting seniors with a greater prevalance. Females are more affected than males and a growing number of young people.
CauseMainly caused by the conditions of modern life. Intensive use of screens (smart phone and computer)/ Pollution / Artificial lights, driving cars / Windy, hot or dry weather conditions and air-conditionned rooms / Contact lenses / Hormonal changes / Medications / Laser eye surgeries
Existing treatments and patients behaviorDue to a lack of preventive treatments, patients are waiting for their symptoms to become serious before visiting an eyecare specialist. Unfortunately, at that stage, existing solutions are often inadequate providing only temporary relief.
Short-term relief: eye dropAvailable treatments mainly involve artificial eye drops. In addition, those are often stringent and insufficient to overcome the discomfort felt by patients.
Long-term relief: E-Eye IRPL®Since 2013, a new non invasive treatment using IRPL® (Intense Regulated Pulsed Light) technology is available. E-Eye, developed and manufactured in France, is quick, gentle and offers long-lasting relief to dry eye sufferers.
- Foreign body sensation
- Blurred vision
- Itchy, scratchy eyes
Complication (if the disorder is not treated)
- Increase in vision disorders.
- Feeling of "eye burning" stopping any visual work.
- Permanent discomfort.
- Paradoxal tear increase.
- Inability to wear contact lenses.
- Anatomical modifications.
- Atrophy of the meibomian glands orifices.
- Episodical infections, sties, conjunctival secondary infections, chalazion.
- Apparition of micro-ulcerations of the epithelium cornea.
How does it work?E-Eye does not directly affect the Meibomian glands. Its action is indirect. The "flashed" areas (buborbital and zygomatic region) are the areas where the parasympathetic nerve passes. It has been proven in several neurological studies that the emission on a nerve of infrared as a train of pulse leads to the creation of a micro gradient of temperature between the inner and the outer layer of the myelin sheath. This micro gradient of temperature triggers the liberation of neurotransmitters. Automatically, the parasympatic nerve is connected to the Meibomian gland by some of its branches. The neurotransmitters released will then be able to interact with the glands, stimulating the secretion and the contraction of the latter. As a result the dry lipid layer will have a natural flow of lipid and the tears evaporation will be reduced, preventing the eyes to get dry. The Meibomian glands will return to their normal functions.
The latest IRPL® technologyE-Eye is a medical device that has been specifically designed for treating dry eye syndrome due to MGD. It generates an Intense Regulated Pulsed Light by producing perfectly calibrated and homogeneously sequenced light pulses. The sculpted pulses are delivered under the shape of train pulses. The energy, spectrum and time period are precisely set to stimulate the Meibomian glands in order for them to return their normal function. E-Eye is a tool for treating and preventing dry eyes.
Made in France100% developed and made in France by E-Swin, the world largest IPL device manufacturer. E-Swin, has an ISO 9001 certification for the Quality of their Management System to ensure they meet the needs of their customers. E-Swin also has an ISO 13485 certification for the design and manufacturing of medical devices.
Our certificationsE-Swin has been an ISO 9001 and ISO 13485 certified company since 2008. Every device we sell carries the European "CE" marking, belong to the "medical devices" category. Manufacturing a product in line with the requirements of ISO 13485 as well as ISO 9001 allows for full traceability, not only of all of our devices sold but also of all of their components. Quality control of each of the components of our devices carrying the medical certification is carried out during the manufacture of each component, at the time of delivery of these components and via numerous tests following their integration into the final device.
E-Eye WorldwideSince the launch of international sales in 2013, E-Eye has set up in many countries. E-Eye is a proven solution now available in more than 45 countries around the world ! More than 50.150 treatments were already done, of which more than 37.000 treatments in 2016.
- No. 1 dry eye solution to treat Meibomian Gland Dysfunction (MGD).
- In 2015, over 35,000 patients have been treated with the E-Eye worldwide!
- 84% efficiency from the first session.
- + 86% satisfaction rate, proven efficiency on mild, medium and severe dry eye.
- 3 clinical studies contucted on over 300 people.
- Up to 18 month relief for your patient.
- More than 100% increase in the break-up time.
- 100% satisfaction amongst users.